Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Ver. Summary Created by Modification Content Size Created at Operation
1 + 514 word(s) 514 2020-12-15 07:45:52

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Zhou, V. BCR Gene. Encyclopedia. Available online: (accessed on 09 December 2023).
Zhou V. BCR Gene. Encyclopedia. Available at: Accessed December 09, 2023.
Zhou, Vicky. "BCR Gene" Encyclopedia, (accessed December 09, 2023).
Zhou, V.(2020, December 24). BCR Gene. In Encyclopedia.
Zhou, Vicky. "BCR Gene." Encyclopedia. Web. 24 December, 2020.
BCR Gene

BCR, RhoGEF and GTPase activating protein


1. Normal Function

The BCR gene provides instructions for making a protein whose function is not completely understood. Studies show that the BCR protein may act as a GTPase activating protein (GAP). GAPs turn off (inactivate) proteins called GTPases, which play an important role in chemical signaling within cells. Often referred to as molecular switches, GTPases can be turned on and off. They are turned on (active) when they are attached (bound) to a molecule called GTP and are turned off when they are bound to another molecule called GDP. The BCR protein inactivates a GTPase known as Rac1 by stimulating a reaction that turns the attached GTP into GDP. Through this activity, the BCR protein helps regulate the movement (migration) and function of cells.

The BCR protein can also act as a kinase, which is an enzyme that changes the activity of other proteins by adding a cluster of oxygen and phosphorus atoms (a phosphate group) at specific positions. BCR's kinase activity is likely involved in regulating signaling within cells, although its exact role is unclear.

2. Health Conditions Related to Genetic Changes

2.1. Chronic myeloid leukemia

A genetic rearrangement (translocation) involving the BCR gene causes a type of cancer of blood-forming cells called chronic myeloid leukemia. This slow-growing cancer leads to an overproduction of abnormal white blood cells. Common features of the condition include excessive tiredness (fatigue), fever, weight loss, and an enlarged spleen.

The translocation involved in this condition, written as t(9;22), fuses part of the ABL1 gene from chromosome 9 with part of the BCR gene from chromosome 22, creating an abnormal fusion gene called BCR-ABL1. The abnormal chromosome 22, containing a piece of chromosome 9 and the BCR-ABL1 fusion gene, is commonly called the Philadelphia chromosome. The translocation is acquired during a person's lifetime and is present only in the abnormal blood cells. This type of genetic change, called a somatic mutation, is not inherited.

The protein produced from the abnormal fusion gene, called BCR-ABL1, signals for cells to grow and divide and blocks the self-destruction of cells that are abnormal or unneeded. The BCR-ABL1 protein is always turned on, so growth and division of affected blood cells is uncontrolled, leading to overproduction of the abnormal cells.

The presence of the Philadelphia chromosome provides a target for molecular therapies.

2.2. Other cancers

The BCR-ABL1 fusion gene (described above) is also involved in fast-growing blood cell cancers called acute leukemias. It has been found in 5 percent of children and up to 30 percent of adults with B-cell acute lymphoblastic leukemia and very rarely in acute myeloid leukemia. As in chronic myeloid leukemia, the BCR-ABL1 protein stimulates overproduction of abnormal white blood cells, leading to cancer. It is likely that the form of blood cancer that develops is influenced by the type of blood cell that acquires the mutation and other genetic changes that occur.

3. Other Names for This Gene

  • ALL
  • BCR/FGFR1 chimera protein
  • BCR1
  • breakpoint cluster region
  • breakpoint cluster region protein isoform 1
  • breakpoint cluster region protein isoform 2
  • CML
  • D22S11
  • D22S662
  • FGFR1/BCR chimera protein
  • PHL
  • renal carcinoma antigen NY-REN-26


  1. Barbers RG, Shih WW, Saxon A. In vitro depression of human lymphocyte mitogen response (phytohaemagglutinin) by asbestos fibres. Clin Exp Immunol. 1982Jun;48(3):602-10.
  2. Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015Apr;94 Suppl 2:S107-21. doi: 10.1007/s00277-015-2325-z.
  3. Diekmann D, Brill S, Garrett MD, Totty N, Hsuan J, Monfries C, Hall C, Lim L, Hall A. Bcr encodes a GTPase-activating protein for p21rac. Nature. 1991 May30;351(6325):400-2.
  4. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity andtransformation potency of bcr-abl oncogene products. Science. 1990 Mar2;247(4946):1079-82.
  5. Maru Y, Witte ON. The BCR gene encodes a novel serine/threonine kinaseactivity within a single exon. Cell. 1991 Nov 1;67(3):459-68.
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 468
Entry Collection: MedlinePlus
Revision: 1 time (View History)
Update Date: 24 Dec 2020